| Abstrakt: |
A recent report from Cairo University discusses the effectiveness and safety of SOF/VEL-containing regimens for the retreatment of chronic HCV-GT4 patients who have previously failed NS5A inhibitors-based therapy. The study included 150 patients, with 50% having liver cirrhosis. The primary outcome, sustained virologic response at 12 weeks (SVR12), was achieved by 96% of the patients. Mild adverse events were reported in 31 patients, with hyperbilirubinemia being the most common in the SOF/VEL + RBV group. The researchers concluded that retreatment with SOF/VEL/VOX for non-cirrhotic patients and SOF/VEL + RBV for cirrhotic patients after the failure of first-line NS5A-based therapy was an effective and well-tolerated treatment option. [Extracted from the article] |
